Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroshi Wakui
Observed name:
Wakui, Hiroshi
Institution:
Jikei University School of Medicine
Observed institution:
Jikei University School of Medicine
ORCID:
0000-0002-3729-1716
Observed ORCID:
0000-0002-3729-1716
OpenAlex ID:
A5024974883
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
·
Clinical Cancer Research
·
25
PDF
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older
2024
·
Shigehiro Yagishita
, Yuta Yamanaka
, et al.
·
Clinical Pharmacology & Therapeutics
·
7
A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B.
2024
·
Go Saito
, Ryo Ko
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer
2026
·
Yutaka Fujiwara
, Katsunori Oikado
, et al.
·
The Oncologist
·
1
Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report
2026
·
Minori Takamura
, Kentaro Tamura
, et al.
·
JTO Clinical and Research Reports
·
1
PDF
Identification of poor prognostic factors using circulating extracellular vesicles in durvalumab consolidation therapy for locally advanced non-small cell lung cancer
2025
·
Hirofumi Utsumi
, Shigehiro Yagishita
, et al.
·
Lung Cancer
·
1
PDF
Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
2024
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
·
Cancer Research
·
1
Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer
2026
·
Shinichi Sasaki
, Katsunori Oikado
, et al.
·
Cancer Medicine
PDF
Supplementary Data1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Data from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
Phase I and early phase II study of enhancing immune checkpoint inhibitor efficacy using a Mycobacterium tuberculosis extract combined with radiation therapy in non-small cell lung cancer patients: NEJ046A
2026
·
Atsuto Mouri
, Jun Sugisaka
, et al.
·
Lung Cancer
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer
2026
·
Hiroto Hatano
, Tatsuya Yoshida
, et al.
·
Lung Cancer
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
2026
·
Atsushi Horiike
, Hiroshi Wakui
, et al.
·
Clinical Cancer Research
Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B)
2026
·
Go Saito
, Ryo Ko
, et al.
·
Lung Cancer
Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Figure S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
PDF
Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024
·
Shinji Nakamichi
, Kaoru Kubota
, et al.
Show more works
View as search
Works count:
29
Citation count:
38
H-index:
2
I10-index:
1
Year
Topic
Type